Voyager Therapeutics, Inc.
VYGR Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 23, 2026
$1.74
KIRA · Stoqly’s AI analyst, in plain words
- Voyager Therapeutics, Inc. had $40.4M of revenue in fiscal 2025, down 49.5% on the year before. Over five years, revenue changed −25.1% a year on average.
- Its operating margin was −326.6%, down 222.4 pts: of every 100 in sales, about −327 is left after running the business.
- Voyager Therapeutics, Inc. lost $120M in fiscal 2025.
- Free cash flow was −$135M in fiscal 2025, −334.5% of revenue.
Market cap
$105M
P/E
—
Revenue
$40.4M
Net income
−$120M
Free cash flow
−$135M
Operating margin
−326.6%
Voyager Therapeutics, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−49.5%
No. Sales fell 49.5% last year.
Does it make a profit?
−296.5%
No. It lost money last year.
Does profit turn into cash?
−334.5%
No. It spent more cash than it brought in.
How healthy are the accounts?
1 / 7
Weak. It passes 1 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Voyager Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 9, 2026
- Legal name
- Voyager Therapeutics, Inc.
- CIK
- 0001640266
Voyager Therapeutics, Inc. · VYGR
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $37.4M | $40.9M | $250M | $80.0M | $40.4M |
| Revenue growth | −78.1% | 9.3% | 511.2% | −68.0% | −49.5% |
| Operating margin | −196.8% | −124.3% | 48.8% | −104.1% | −326.6% |
| Net income | −$71.2M | −$46.4M | $132M | −$65.0M | −$120M |
| Net margin | −190.3% | −113.4% | 52.9% | −81.3% | −296.5% |
| Diluted EPS | −$1.89 | −$1.21 | $2.97 | −$1.13 | −$2.04 |
| Cash | |||||
| Cash from operations | −$53.5M | −$12.5M | $77.9M | −$15.3M | −$132M |
| Capital expenditure | $1.6M | $2.5M | $3.3M | $3.5M | $2.6M |
| Free cash flow | −$55.1M | −$15.0M | $74.7M | −$18.8M | −$135M |
| FCF margin | −147.4% | −36.7% | 29.9% | −23.5% | −334.5% |
| Share count change | 0.9% | 1.8% | 16.2% | 29.4% | 1.8% |
| Debt and strength | |||||
| Cash and short-term investments | $133M | $119M | $231M | $267M | $196M |
| Shareholders' equity | $95.1M | $59.0M | $236M | $300M | $196M |
| Current ratio | 2.7x | 1.7x | 5.0x | 5.6x | 7.6x |
| Returns and quality | |||||
| Return on equity | −57.1% | −60.2% | 89.6% | −24.3% | −48.3% |
| Return on tangible equity | −74.9% | −78.6% | 56.0% | −21.7% | −61.1% |
| Piotroski F-score | 1 | 3 | 5 | 2 | 1 |
| Altman Z'' | −4.5 | −7.4 | 6.8 | 3.0 | −1.0 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.3M
4 insiders
Of sales under plans
74%
$0.2M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Voyager Therapeutics, Inc. · VYGR
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.74 a share, the company is worth $105M.
Source: SEC EDGAR XBRL filings (CIK 0001640266). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.